Prognostic role of microRNA-31 in various cancers: a meta-analysis

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11639-11645

  Wang, Shuwei ^a   Hu, Jun ^a   Zhang, Dongsheng ^a   Li, Juan ^a   Fei, Qiang ^a   Sun, Yueming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Meta analysis; MicroRNA 31; Prognostic; Survival

Indexed keywords

MICRORNA; MIRN31 MICRORNA, HUMAN; TUMOR MARKER;

CASE CONTROL STUDY; GENETICS; HUMAN; META ANALYSIS; MORTALITY; NEOPLASM; PROGNOSIS; SURVIVAL RATE;

CASE-CONTROL STUDIES; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84927797178     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2492-x     Document Type: Article

References (35)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.
3. Okumura T, Shimada Y, Moriyama M, Takei Y, Omura T, Sekine S, et al. MicroRNA-203 inhibits the progression of esophageal squamous cell carcinoma with restored epithelial tissue architecture in vivo. Int J Oncol. 2014;44(6):1923–32. doi:10.3892/ijo.2014.2365.
4. Mei Z, He Y, Feng J, Shi J, Du Y, Qian L. MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2. FEBS Lett. 2014. doi:10.1016/j.febslet.2014.06.020.
5. Zhang W, Liu J, Wang G. The role of microRNAs in human breast cancer progression. Tumour Biol: J Int Soc Oncodev Biol Med. 2014. doi:10.1007/s13277-014-2202-8.
6. Ishiguro H, Kimura M, Takeyama H. Role of microRNAs in gastric cancer. World J Gastroenterol: WJG. 2014;20(19):5694–9. doi:10.3748/wjg.v20.i19.5694.
7. Wang N, Zhou Y, Zheng L, Li H. MiR-31 is an independent prognostic factor and functions as an oncomir in cervical cancer via targeting ARID1A. Gynecol Oncol. 2014. doi:10.1016/j.ygyno.2014.04.047.
8. Karnuth B, Dedy N, Spieker T, Lawlor ER, Gattenlohner S, Ranft A, et al. Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion. PLoS One. 2014;9(3):e93067. doi:10.1371/journal.pone.0093067.
9. Sun D, Yu F, Ma Y, Zhao R, Chen X, Zhu J, et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem. 2013;288(13):9508–18. doi:10.1074/jbc.M112.367763.
10. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120(4):1298–309. doi:10.1172/JCI39566.
11. Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol: Off Publi Fed Span Oncol Soc National Cancer Inst Mex. 2013;15(10):849–54. doi:10.1007/s12094-013-1014-4.
12. Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013;73(3):1232–44. doi:10.1158/0008-5472.CAN-12-2968.
13. Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK. microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway. Mol Cancer. 2014;13(1):97. doi:10.1186/1476-4598-13-97.
14. Yang MH, Yu J, Chen N, Wang XY, Liu XY, Wang S, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One. 2013;8(12):e85353. doi:10.1371/journal.pone.0085353.
15. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis. 2014;35(4):776–83. doi:10.1093/carcin/bgt374.
16. Izquierdo L, Ingelmo-Torres M, Mallofre C, Lozano JJ, Verhasselt-Crinquette M, Leroy X, et al. Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int. 2014;113(5):813–21. doi:10.1111/bju.12551.
17. Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19(19):5423–33. doi:10.1158/1078-0432.CCR-13-0320.
18. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(21):6802–11. doi:10.1158/1078-0432.CCR-11-0419.
19. Wang S, Jiao B, Geng S, Song J, Liang Z, Lu S. Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas. J Neurol Sci. 2014;338(1–2):71–6. doi:10.1016/j.jns.2013.12.019.
20. Zhang T, Wang Q, Zhao D, Cui Y, Cao B, Guo L, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond). 2011;121(10):437–47. doi:10.1042/CS20110207.
21. Yu H, Jiang L, Sun C, Guo L, Lin M, Huang J. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2013. doi:10.1016/j.gene.2013.10.024.
22. Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF, Huang WZ, et al. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma. J Surg Oncol. 2012;105(2):175–82. doi:10.1002/jso.22066.
23. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol: J Int Soc Oncodev Biol Med. 2013;34(4):2175–81. doi:10.1007/s13277-013-0753-8.
24. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013;52(4):297–303. doi:10.1002/mc.21864.
25. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA:J Am Med Assoc. 2000;283(15):2008–12.
26. Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, et al. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. J Experiment Clin Cancer Res: CR. 2013;32(1):71. doi:10.1186/1756-9966-32-71.
27. Kim DJ, Linnstaedt S, Palma J, Park JC, Ntrivalas E, Kwak-Kim JY, et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Molec Diagn: JMD. 2012;14(1):71–80. doi:10.1016/j.jmoldx.2011.09.002.
28. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1–12. doi:10.1016/j.ydbio.2006.08.028.
29. Hong L, Han Y, Li S, Yang J, Zheng J, Zhang H, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther. 2010;10(12):1693–701. doi:10.1517/14712598.2010.532482.
30. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X. miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Experiment Ther Med. 2013;6(5):1265–70. doi:10.3892/etm.2013.1311.
31. Zhong Z, Dong Z, Yang L, Chen X, Gong Z. MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol:J Int Soc Oncodev Biol Med. 2013;34(3):1959–65. doi:10.1007/s13277-013-0741-z.
32. Vire E, Curtis C, Davalos V, Git A, Robson S, Villanueva A, et al. The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol Cell. 2014;53(5):806–18. doi:10.1016/j.molcel.2014.01.029.
33. Dong Z, Zhong Z, Yang L, Wang S, Gong Z. MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett. 2014;343(2):249–57. doi:10.1016/j.canlet.2013.09.034.
34. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6(4):375–92.
35. Trikalinos TA, Hoaglin DC, Schmid CH. Empirical and simulation-based comparison of univariate and multivariate meta-analysis for binary outcomes. Rockville: AHRQ Methods for Effective Health Care; 2013.